Skip Navigation LinksHome > October/December 2013 - Volume 38 - Issue 4 > The business case for provider participation in clinical tri...
Health Care Management Review:
doi: 10.1097/HMR.0b013e31827292fc
Features

The business case for provider participation in clinical trials research: An application to the National Cancer Institute’s community clinical oncology program

Song, Paula H.; Reiter, Kristin L.; Weiner, Bryan J.; Minasian, Lori; McAlearney, Ann Scheck

Collapse Box

Abstract

Background:

Provider-based research networks (PBRNs) make clinical trials available in community-based practice settings, where most people receive their care, but provider participation requires both financial and in-kind contributions.

Purpose:

The aim of this study was to explore whether providers believe there is a business case for participating in PBRNs and what factors contribute to the business case.

Methodology/Approach:

We use a multiple case study methodology approach to examine the National Cancer Institute’s community clinical oncology program, a long-standing federally funded PBRN. Interviews with 41 key informants across five sites, selected on the basis of organizational maturity, were conducted using a semistructured interview guide. We analyzed interview transcripts using an iterative, deductive process to identify themes and subthemes in the data.

Findings:

We found that a business case for provider participation in PBRNs may exist if both direct and indirect financial benefits are identified and included in the analysis and if the time horizon is long enough to allow those benefits to be realized. We identified specific direct and indirect financial benefits that were perceived as important contributors to the business case and the perceived length of time required for a positive return to accrue.

Practice Implications:

As the lack of a business case may result in provider reluctance to participate in PBRNs, knowledge of the benefits we identified may be crucial to encouraging and sustaining participation, thereby preserving patient access to innovative community-based treatments. The results are also relevant to federally funded PBRNs outside of oncology or to providers considering participation in any clinical trials research.

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.